111 (NASDAQ:YI), Inc. (NASDAQ:YI) operates as a leading online pharmaceutical and healthcare services platform in China. Through its proprietary e-commerce portal and mobile applications, the company offers a broad range of prescription and over-the-counter medications, healthcare products, medical devices, and nutritional supplements. Its digital infrastructure integrates telemedicine consultations, electronic prescriptions, and real-time order tracking, enabling patients to receive timely access to essential treatments without visiting physical pharmacies.
At the core of 111’s business model is an omnichannel distribution network that combines online ordering with a network of partner warehouses and affiliated retail pharmacies. This hybrid approach allows the company to fulfill orders across China’s major urban centers and more remote regions, ensuring same-day or next-day delivery for many customers. In addition to pharmaceutical sales, 111 offers value-added services such as chronic disease management programs, medication adherence reminders, and personalized health education content designed to support long-term patient outcomes.
Founded in the early 2010s and headquartered in Shanghai, 111 has grown rapidly by leveraging China’s digital transformation in healthcare. The company has continually invested in data analytics and artificial intelligence to optimize inventory management, tailor marketing to consumer needs, and enhance its telehealth consultation capabilities. Its platform also integrates with third-party health insurance and payment providers, simplifying reimbursement processes for users and expanding its reach among both urban professionals and elderly patients.
111 is led by a management team with extensive experience in pharmaceuticals, e-commerce, and healthcare technology. Under their guidance, the company has forged strategic partnerships with domestic hospitals, healthcare institutions, and logistics providers. As regulatory frameworks evolve in China’s online pharmacy sector, 111 is well positioned to capitalize on increased consumer adoption of digital health services and continued government support for Internet-based medical innovations.
